Literature DB >> 29957934

Stereocomplex Prodrugs of Oligo(lactic acid) n-Gemcitabine in Poly(ethylene glycol)- block-poly(d,l-lactic acid) Micelles for Improved Physical Stability and Enhanced Antitumor Efficacy.

Yu Tong Tam1, Chengbin Huang1, Michael Poellmann1, Glen S Kwon1.   

Abstract

Herein we demonstrate the formation of stereocomplex prodrugs of oligo(l-lactic acid) n-gemcitabine (o(LLA) n-GEM) and oligo(d-lactic acid) n-gemcitabine (o(DLA) n-GEM) for stable incorporation in poly(ethylene glycol)- block-poly(d,l-lactic acid) (PEG- b-PLA) micelles. O(LLA) n or o(DLA) n was attached at the amino group (4-( N)) of GEM via an amide linkage. When n = 10, a 1:1 mixture of o(LLA)10-GEM and o(DLA)10-GEM (o(L+DLA)10-GEM) was able to form a stereocomplex with a distinctive crystalline pattern. Degradation of o(L+DLA)10-GEM was driven by both backbiting conversion and esterase contribution, generating primarily o(L+DLA)1-GEM and GEM. O(L+DLA)10-GEM stably loaded in PEG- b-PLA micelles in the size range of 140-200 nm with an unexpected elongated morphology. The resulting micelles showed improved physical stability in aqueous media and inhibited backbiting conversion of o(L+DLA)10-GEM within micelles. Release of o(L+DLA)10-GEM from micelles was relatively slow, with a t1/2 at ca. 60 h. Furthermore, weekly administration of o(L+DLA)10-GEM micelles i.v. displayed potent antitumor activity in an A549 human non-small-cell lung carcinoma xenograft model. Thus, stereocomplexation of isotactic o(LLA) n and o(DLA) n acts as a potential prodrug strategy for improved stability and sustained drug release in PEG- b-PLA micelles.

Entities:  

Keywords:  backbiting conversion; gemcitabine; oligo(lactic acid)n (o(LA)n); poly(ethylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA); polymeric micelles; prodrug; stereocomplex

Mesh:

Substances:

Year:  2018        PMID: 29957934      PMCID: PMC6071312          DOI: 10.1021/acsnano.8b04205

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  21 in total

Review 1.  Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications.

Authors:  Elodie Moysan; Guillaume Bastiat; Jean-Pierre Benoit
Journal:  Mol Pharm       Date:  2012-10-08       Impact factor: 4.939

2.  Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.

Authors:  Maria Laura Immordino; Paola Brusa; Flavio Rocco; Silvia Arpicco; Maurizio Ceruti; Luigi Cattel
Journal:  J Control Release       Date:  2004-12-10       Impact factor: 9.776

3.  Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles.

Authors:  Ling Xiao; Xiaoqin Xiong; Xiaohui Sun; Yanhong Zhu; Hao Yang; Huabing Chen; Lu Gan; Huibi Xu; Xiangliang Yang
Journal:  Biomaterials       Date:  2011-05-04       Impact factor: 12.479

4.  Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.

Authors:  Barbara Pili; L Harivardhan Reddy; Claudie Bourgaux; Sinda Lepêtre-Mouelhi; Didier Desmaële; Patrick Couvreur
Journal:  Nanoscale       Date:  2010-07-05       Impact factor: 7.790

5.  Squalenoyl nanomedicines as potential therapeutics.

Authors:  Patrick Couvreur; Barbara Stella; L Harivardhan Reddy; Hervé Hillaireau; Catherine Dubernet; Didier Desmaële; Sinda Lepêtre-Mouelhi; Flavio Rocco; Nathalie Dereuddre-Bosquet; Pascal Clayette; Véronique Rosilio; Véronique Marsaud; Jack-Michel Renoir; Luigi Cattel
Journal:  Nano Lett       Date:  2006-11       Impact factor: 11.189

6.  Biodegradable dextran hydrogels crosslinked by stereocomplex formation for the controlled release of pharmaceutical proteins.

Authors:  W E Hennink; S J De Jong; G W Bos; T F J Veldhuis; C F van Nostrum
Journal:  Int J Pharm       Date:  2004-06-11       Impact factor: 5.875

7.  Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine.

Authors:  L Harivardhan Reddy; Pierre-Emmanuel Marque; Catherine Dubernet; Sinda-Lepêtre Mouelhi; Didier Desmaële; Patrick Couvreur
Journal:  J Pharmacol Exp Ther       Date:  2008-02-07       Impact factor: 4.030

8.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

Authors:  J L Abbruzzese; R Grunewald; E A Weeks; D Gravel; T Adams; B Nowak; S Mineishi; P Tarassoff; W Satterlee; M N Raber
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

9.  Structural reorganization of cylindrical nanoparticles triggered by polylactide stereocomplexation.

Authors:  Liang Sun; Anaïs Pitto-Barry; Nigel Kirby; Tara L Schiller; Ana M Sanchez; M Adam Dyson; Jeremy Sloan; Neil R Wilson; Rachel K O'Reilly; Andrew P Dove
Journal:  Nat Commun       Date:  2014-12-17       Impact factor: 14.919

10.  Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles.

Authors:  Yingzhe Wang; Wei Fan; Xin Dai; Usha Katragadda; DeAngelo Mckinley; Quincy Teng; Chalet Tan
Journal:  Mol Pharm       Date:  2014-03-10       Impact factor: 4.939

View more
  1 in total

Review 1.  Nanoparticulation of Prodrug into Medicines for Cancer Therapy.

Authors:  Yuezhou Zhang; Huaguang Cui; Ruiqi Zhang; Hongbo Zhang; Wei Huang
Journal:  Adv Sci (Weinh)       Date:  2021-07-29       Impact factor: 16.806

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.